Quest Diagnostics Incorporated
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James E. Davis
- Full Time Employees
- 57,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 500 Plaza Drive Secaucus NJ United States of America 07094
- IPO Date
- Dec 17, 1996
- CIK
- 0001022079
- Website
- questdiagnostics.com
- Similar Companies
- Business
- Quest Diagnostics Incorporated (NYSE: DGX) provides diagnostic information services, including routine, non-routine, and advanced clinical laboratory testing; anatomic pathology testing; and related healthcare insights derived from one of the world's largest clinical lab databases. The company offers an industry-leading menu of tests across specialties such as endocrinology, immunology, neurology, oncology, infectious diseases (including COVID-19 molecular and serology testing, tuberculosis via T-SPOT.TB and Quantiferon, and tick-borne diseases via Accutix), drug monitoring and toxicology (as the largest U.S. workplace drug testing provider for urine, hair, and oral fluid specimens), cardiovascular diagnostics through its CardioIQ and Cleveland HeartLab offerings at the Cardiometabolic Center of Excellence, and cancer diagnostics via QuestVantage; it also delivers employer population health services like biometric screenings and flu shots, Quanum health IT solutions for data analytics and clinician connectivity, population health tools including Quest Lab Stewardship for test optimization and extended care services such as bone density exams and home collection kits, and pharmaceutical support encompassing clinical trials testing, companion diagnostics development, and Quest Clinical Trials Connect for patient recruitment. Operations span a nationwide network of full-service and rapid-response laboratories, over 2,000 patient service centers, mobile phlebotomists, and in-house experts providing consultation; the company serves one in three adult Americans and half of U.S. physicians and hospitals annually, with additional reach through the Global Diagnostic Network in countries including Puerto Rico, Mexico, Brazil, and Canada. Founded in 1967 as Metropolitan Pathology Laboratory in New York City and headquartered in Secaucus, New Jersey, Quest Diagnostics spun off from Corning in 1996 as an independent public company and employs nearly 50,000 people. It targets physicians, hospitals, employers, health plans, integrated delivery networks, and pharmaceutical firms across segments like general clinical testing, esoteric and gene-based assays, wellness services, and advanced diagnostics for chronic and infectious diseases. Recent developments include the 2023 acquisition of Haystack Oncology to integrate sensitive minimal-residual disease (MRD) liquid biopsy technology for solid tumor cancer detection into its portfolio, with services launching in 2024; the acquisition of select assets from Steward Health Care's outreach lab services in early 2024 to expand access; the May 2024 agreement to acquire PathAI Diagnostics, enhancing AI-powered digital pathology capabilities for faster cancer diagnosis, quality improvement, and extension into dermatopathology, gastrointestinal, and urological areas; and the 2024 announcement to acquire LifeLabs, Canada's leading diagnostics provider, from OMERS Infrastructure to broaden North American operations and advanced testing access. In 2022, the company acquired Pack Health to bolster patient engagement services for pharma clients and population health, alongside collaborations like retinal imaging with IRIS for diabetic retinopathy screening. These moves strengthen Quest's leadership in oncology, AI innovation, and geographic expansion amid a focus on data-driven insights and preventive care.
Are You Looking for a Top Momentum Pick? Why Quest Diagnostics (DGX) is a Great Choice
Why Quest Diagnostics (DGX) is a Top Momentum Stock for the Long-Term
Quest Diagnostics Incorporated (DGX) Soars to 52-Week High, Time to Cash Out?
Quest Diagnostics Upgrades EPS Outlook For 2026 After Outperforming Q2 Results
Quest Diagnostics Q2 Earnings Call Highlights
Quest Diagnostics Incorporated (DGX) Q2 2026 Earnings Call Transcript
Americans Are Buying More Preventive Health Tests—and Quest Diagnostics Is Winning
DGX Stock Up on Q2 Earnings & Revenue Beat, '26 View Raised
Quest Diagnostics (DGX) Surpasses Q2 Earnings and Revenue Estimates
Quest Diagnostics raises annual forecast on testing demand
Breakfast News: The Catch In Alphabet's Results
Is Quest Diagnostics Inc (DGX) Overvalued After Q2 Earnings Beat? EPS at $2.84, Revenue at $3.04 Billion, GF Score: 80/100
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
5 High Dividend Yield Stocks to Buy for a Stable Portfolio in 2H 2026
Dividend Champion, Contender, And Challenger Highlights: Week Of July 19
Quest Diagnostics to Report Q2 Earnings: Key Customer Channels in Focus
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?